Application of beta-interferon to medicament making

A technology for interferon and use, which is applied in the field of medical use of beta-interferon, and can solve problems such as toxic side effects and clinical treatment limitations

Inactive Publication Date: 2011-04-13
SHANGHAI INST OF IMMUNOLOGY +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the clinical dose of this type of drug is slightly larger and the course of treatment is sli

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of beta-interferon to medicament making
  • Application of beta-interferon to medicament making
  • Application of beta-interferon to medicament making

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Embodiment 1 Quantitative PCR detects TCR BV

[0064] The RNA of peripheral blood mononuclear cells was extracted according to the operating instructions of Qiagen Company RNeasy Mini Kit; then according to TAKARA Company PrimeScript TM Operating instructions of the RNA reverse transcription kit Reverse transcribe the obtained RNA to obtain cDNA.

[0065] Before and after IFN-β intervention, the cDNA of peripheral blood mononuclear cells of RA patients was analyzed by quantitative PCR. It was found that before and after the intervention, although TCR BV13 was predominantly expressed, the expression of TCR BV13 (Pfigure 1 ).

Embodiment 2I

[0066] Example 2 CD3 before and after IFN-β intervention + Changes in T cell proliferation

[0067] The various conjugated peptides were synthesized by Jill Biochemical (Shanghai) Co., Ltd., with a purity greater than 95%.

[0068] CD3 + T cells were seeded in a 96-well round-bottom plate at a density of 1×10 5 cells / well, the non-CD3 cells after sorting by magnetic beads + Irradiated T cells, as APC (CD3 + T:APC=2:1). Various synthetic coupling peptides (see Table 2) were added to the culture system at a final concentration of 40 μg / ml, and a small amount of IL-2 was added. Place at 37 °C 5% CO 2 Incubator for 7 days. 16-18 hours before antigenic peptide stimulation for 7 days, add 1 μCi of [ 3 H]-TdR. Cells were collected and detected by a β liquid scintillation instrument[ 3 CPM values ​​for H]-TdR incorporation.

[0069] Experiments have proved that the conjugated peptide with HLA-Dw4 / EBV functional domain can significantly induce CD3 in RA patients + The role ...

Embodiment 3I

[0070] Changes of cytokines before and after the intervention of embodiment 3 IFN-β

[0071] RA intervention group: Before IFN-β intervention, three cytokines in serum and synovial fluid were detected, including IL-17 mainly secreted by Th17 cells; negative regulator IL-10; and inflammatory cells secreted by Th1 cells Factor IFN-γ. One week after IFN-β intervention, IL-17, IL-10 and IFN-γ in serum and synovial fluid were detected again. The results of the analysis and comparison are shown in Table 3.

[0072] In the experiment, according to the corresponding kit, with the concentration as the abscissa and the measured average value as the ordinate, the standard curves of IL-177, IL-10 and IFN-γ are respectively: Y=0.032+0.001X, Y=0.155 +0.007X and Y=-0.024+0.001X.

[0073] Table 3 Change trend of IL-17, IL-10 and IFN-γ in serum and synovial fluid of RA patients

[0074]

[0075] Note: ↑ indicates the level of cytokines after IFN-β intervention, which is higher than that...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the application of beta-interferon to medicament making. After the immunological effect substances is immunized and intervened by the beta-interferon, the levels of the immunological effect substances which are closely related to a rheumatoid arthritis disease, such as a T lymphocyte antigen receptor, autoreactivity CD3+T cell proliferation, matrix metalloproteinase and a nuclear factor kB and receptor activating factor ligand are obviously reduced in serum and focal synovia of a patient, thereby the beta-interferon can be used for immunizing, intervening and treating rheumatoid arthritis.

Description

technical field [0001] The invention relates to the medical use of a beta-interferon, in particular to the application of a beta-interferon as a medicine in immune intervention and treatment of rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (Rheumatoid Arthritis-RA) is an autoimmune disease with unknown etiology mainly invading limb joints, and its incidence rate is as high as 0.4%-1%. The current traditional medicines for the treatment of rheumatoid arthritis are divided into four categories; non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), glucocorticoids and botanicals. Glucocorticoids are traditional drugs for the treatment of rheumatoid arthritis, but their wide application is limited due to severe side effects and rebound after drug withdrawal. Disease-modifying anti-rheumatoid arthritis drugs (DMARDs) are very beneficial for controlling the disease and reducing or slowing down the destruction of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/21A61P19/02A61P19/04A61P29/00
Inventor 张冬青何东仪许荣余奇文肖涟波沈杰张继英钱柳陈雪华程伟志胡朝英黄秋愉
Owner SHANGHAI INST OF IMMUNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap